Europe's Health Agency Accepts Moderna's Filing For Its Updated Omicron-Targeted COVID-19 Vaccine

Europe's Health Agency Accepts Moderna's Filing For Its Updated Omicron-Targeted COVID-19 Vaccine
  • The European Medicines Agency (EMA) has accepted a variation for evaluating Moderna Inc's MRNA 50 µg booster dose of the Omicron-containing bivalent COVID booster candidate for individuals 12 years and older. 
  • Spikevax bivalent original/omicron BA.4-5 is a next-generation bivalent vaccine that contains 25 µg of mRNA-1273 (Spikevax) and 25 µg of a vaccine candidate targeting the Omicron variant of concern (BA.4/BA.5).
  • Related: As Moderna Grapples With Supply Shortage, FDA Gives Nod To Additional Lots of COVID-19 Booster.
  • The updated shot, mRNA-1273.222, targets both the original strain of SARS-CoV-2 and the BA.4/BA.5 subvariants of the Omicron strain. 
  • Moderna's submission to the EMA is based on preclinical data for mRNA-1273.222 and clinical trial data from a Phase 2/3 studying Spikevax bivalent Original/Omicron BA.1 (mRNA-1273.214), a bivalent booster vaccine targeting the Omicron BA.1 subvariant, which recently received EMA approval.
  • Last week, Moderna asked the FDA to authorize the use of its updated booster shot in children ages 6 to 17. The company expects to complete a request for the use of the booster in children six months through 5 years later this year.
  • Price Action: MRNA shares are up 1.20% at $123.70 on the last check Wednesday.

Posted In: BriefsEuropean Medicines AgencyBiotechLarge CapNewsHealth CareGeneral